|
| Press Releases |
|
 |
|
| Tuesday, December 1, 2020 |
|
|
BioVaxys Provides Viral Vaccine Platform Program Update |
| BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
| Monday, November 30, 2020 |
|
|
BioVaxys Provides Viral Vaccine Platform Program Update |
| BioVaxys Technology Corp. (CSE: BIOV) is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
| Wednesday, November 11, 2020 |
|
|
BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine |
| BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys") is pleased to announce that results from its preclinical animal study (also known as the "murine model study") of BVX-0320, its Covid-19 vaccine candidate, show that the vaccine elicits a positive immune response against the SARS-CoV-2 s-spike protein. more info >> |
|
| Monday, November 2, 2020 |
|
|
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity |
| BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or "the Company"), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
TANAKA Holds Press Conference to Commemorate Its 140th Anniversary
Aug 15, 2025 3:00 JST
|
|
|
Re-opening of Food Expo and concurrent fairs
Aug 14, 2025 23:42 HKT/SGT
|
|
|
WL Delicious Announced 2025 Interim Results
Aug 14, 2025 23:05 HKT/SGT
|
|
|
RAK ICC Strengthens Foundations Regime with 2025 Legislative Enhancements
Aug 14, 2025 23:00 HKT/SGT
|
|
|
RAK ICC以2025年立法升級加強基金會制度
Aug 14, 2025 23:00 HKT/SGT
|
|
|
RAK ICC以2025年立法升级加强基金会制度
Aug 14, 2025 23:00 HKT/SGT
|
|
|
卫龙美味公佈2025年中期業績
Aug 14, 2025 22:48 HKT/SGT
|
|
|
Cryofocus Medtech Achieves Record Interim Results with 162% Revenue Surge Driven by Respiratory Intervention Products
Aug 14, 2025 22:31 HKT/SGT
|
|
|
卫龙美味公布2025年中期业绩
Aug 14, 2025 22:30 HKT/SGT
|
|
|
Formerra Becomes North American Distributor for Syensqo PVDF
Aug 14, 2025 22:29 HKT/SGT
|
|
|
GEON Performance Solutions Achieves Great Place to Work Recognition Globally Second Year in a Row
Aug 14, 2025 22:28 HKT/SGT
|
|
|
MMG Announces 2025 Interim Results, Profit, Earnings and Cash up on Strong Copper Growth
Aug 14, 2025 22:20 HKT/SGT
|
|
|
Shoucheng Joins World Humanoid Robot Games - 88 Spectators Invited
Aug 14, 2025 22:19 HKT/SGT
|
|
|
FWD Group marks 12th anniversary with 12 community grants
Aug 14, 2025 23:18 JST
|
|
|
AsiaMedic Reports 26% Revenue Growth to S$16.6 million in 1H2025, Led by Strong Diagnostic Imaging Performance
Aug 14, 2025 21:22 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
